Paola Minetto, Carola Riva, Enrico Carminati, Giada Zecchetti, Francesco Puglisi, Clara Nurra, Michele Cea, Roberto Lemoli, Fabio Guolo. "The presence of secondary type or DNMT3A mutations does not affect prognosis in NPM1 mutated AML treated with intensified fludarabine-high dose cytarabine and idarubicine (FLAI) induction regimen.." Blood, 2025. doi:10.1182/blood-2025-1625